Table of Contents Table of Contents
Previous Page  25 / 46 Next Page
Information
Show Menu
Previous Page 25 / 46 Next Page
Page Background

QoL con Radium 223 (ALSYMPCA)

Mean changes in utility and FACT-P total scores from baseline over time indicate that higher QOL observed with

radium-223 patients was a direct consequence of a slower rate of decline in QOL with radium-223 versus placebo.

Nilsson S, et al.

Ann Oncol.

2016;27(5):868-74

EQ-5D UTILITY SCORE

Radium-223

Placebo

0

-0.05

-0.10

-0.15

-0.20

Change from baseline

0

Week 36

(follow-up visit 1)

Week 44

(follow-up visit 2)

Week 24

Week 16

614

300

220

343

460

307

105

84

131

194

P

= 0.242

P

= 0.828

P

= 0.034

P

= 0.004

Ra-223

PBO

FACT-P TOTAL SCORE

Radium-223

Placebo

0

-2

-6

-10

-14

Change from baseline

0

Week 44

(follow-up visit 2)

Week 24

Week 16

614

186

314

407

307

75

120

177

P

= 0.147

P

= 0.112

P

= 0.006

Ra-223

PBO

-12

-8

-4